Catalyst Event
Tempus AI Inc (TEM) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
5/29/2026, 12:00:00 AM
Tempus announced FDA approval on 2026-05-29 for a tumor-only indication for its xT CDx platform, enabling migration of its DNA solid tumor portfolio; shares rose about 3.5% on the news.
Korean Translation
2026-05-29 Tempus가 xT CDx 플랫폼의 종양 단독 적응증에 대한 FDA 승인을 발표해 DNA 고형암 포트폴리오 이전이 가능해졌으며, 해당 소식에 주가가 약 3.5% 상승함.
Related Recent Events
Alphabet Inc (GOOGL) · Earnings Release
Alphabet Q2 2026 earnings release scheduled for July 22, 2026, with analysts forecasting EPS of approximately $2.85-$2.87 forecasted.
7/22/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Other
Alphabet held its 2026 Annual Meeting of Shareholders on June 5, 2026. Proposals included an increase to the 2021 Stock Plan share reserve.
6/5/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Other
Hims & Hers appointed Dr. Anant Vinjamoori as its new Chief Medical Officer on 2026-06-04, which resulted in a 7.23% stock price increase.
6/4/2026, 12:00:00 AM
Natera Inc (NTRA) · Other
Announced a strategic collaboration with CytoDyn to use its ctDNA platform to support CytoDyn's metastatic colorectal cancer development program.
6/4/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Announced on 2026-06-03 plans to halve its €2.3 billion investment in a new German plant; medium impact estimated due to regulatory headwinds and reduced growth capacity, expected.
6/3/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Other
The UK's Competition & Markets Authority (CMA) announced on June 3, 2026, new conduct requirements for Google's AI-powered search, giving publishers more control over their content.
6/3/2026, 12:00:00 AM